MedTrace Logo

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

NCT04442490 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 543

Last updated 2023-12-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

SAGE-217

SAGE-217 oral capsules.

DRUG

Placebo

SAGE-217 matched-placebo oral capsules.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2021-03-26
Completion
2021-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04442490 on ClinicalTrials.gov